Zomedica Corp. (ZOM)
NYSEAMERICAN: ZOM · IEX Real-Time Price · USD
0.142
0.00 (0.28%)
May 2, 2024, 4:00 PM EDT - Market closed
Zomedica Revenue
In the year 2023, Zomedica had annual revenue of $25.19M with 33.05% growth. Revenue in the quarter ending December 31, 2023 was $7.34M with 19.17% year-over-year growth.
Revenue (ttm)
$25.19M
Revenue Growth
+33.05%
P/S Ratio
5.53
Revenue / Employee
$174,903
Employees
144
Market Cap
139.15M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 25.19M | 6.26M | 33.05% |
| Dec 31, 2022 | 18.93M | 14.80M | 358.02% |
| Dec 31, 2021 | 4.13M | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| So-Young International | 211.29M |
| Outset Medical | 130.38M |
| InterCure | 97.95M |
| Repare Therapeutics | 51.13M |
| Biodesix | 49.09M |
| Scilex Holding Company | 46.74M |
| Seer, Inc. | 16.66M |
| Omega Therapeutics | 3.09M |
ZOM News
- 19 hours ago - Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform - Accesswire
- 2 days ago - Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET - Accesswire
- 23 days ago - Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024 - Accesswire
- 4 weeks ago - Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity - Accesswire
- 6 weeks ago - Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET - Accesswire
- 7 weeks ago - Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform - Accesswire
- 7 weeks ago - Zomedica Provides NYSE American Listing Update - Accesswire
- 7 weeks ago - Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences - Accesswire